Table 5.
Effect of PRP concentrations and extender types on post-thaw sperm antioxidant activity and malondialdehyde levels (mean ± SEM)
| Extender | PRP (%) | N | GSH (nmol/l) | TAC (mmol/ml) | MDA (nmol/ml) |
|---|---|---|---|---|---|
| OptiXcell® A | 0% | 48 | 0.71 ± 0.01d | 19.67 ± 0.67d | 23.91 ± 0.48a |
| 5% | 48 | 0.95 ± 0.01c | 21.33 ± 0.42c | 18.23 ± 0.40b | |
| 10% | 48 | 1.49 ± 0.03a | 25.17 ± 0.65a | 11.77 ± 0.29c | |
| 15% | 48 | 1.42 ± 0.02b | 23.33 ± 0.42b | 12.75 ± 0.31c | |
| Tris egg yolk-based B | 0% | 48 | 0.63 ± 0.01d | 17.61 ± 0.49c | 26.28 ± 0.92a |
| 5% | 48 | 0.75 ± 0.03c | 19.77 ± 0.40b | 23.78 ± 0.79b | |
| 10% | 48 | 1.31 ± 0.02a | 22.83 ± 0.54a | 17.50 ± 0.62c | |
| 15% | 48 | 1.16 ± 0.02b | 20.60 ± 0.60b | 19.18 ± 0.40c |
N = 48 ejaculates. Within columns, values with different superscripts differ significantly for each parameter (P < 0.05)
Within the same column, means bearing a, b, c, and d differ among PRP concentrations (0%, 5%, 10% and 15%) within the same extender (OptiXcell® or Tris egg yolk-based). A and B differ between extender types (OptiXcell® or Tris egg yolk-based), at the same PRP concentrations (0%, 5%, 10% and 15%). PRP, Platelet-rich plasma; GSH, Glutathione reductase enzyme; TAC, Total antioxidant capacity; MDA, Malondialdehyde